FOR PHARMACISTS · SCIENTIFIC COLLECTION 10.0310 monographs · 36 SOPs · 22 forms
Sikaliascompounding.grSikalias Greek Formulary
Home / Learning / Clinical excipient assessment and daily exposure · PUB-016

PUB-016 / 1.0

Clinical excipient assessment and daily exposure

Excipient safety depends on actual quantity, route and patient. This review links calculation to current evidence and clinical decisions.

Collection and scientific editing: Stasinos Chr. SikaliasContent edition: 1.0Record editorial review date: 2026-10-14

Download bilingual PDFJSON

Complete identity

Record every excipient, exact chemical form, concentration, unit basis and contribution from commercial vehicles/products. A base name without composition cannot support reliable exposure calculation. Review supplier changes and other sources of the same substance.

Arithmetic example, not prescribing

Arithmetic illustration: 0.5% w/v = 5 mg/mL. At a confirmed maximum daily amount of 8 mL, excipient exposure is 40 mg/day. This illustrates unit conversion, not a recommended medicine dose or safety limit. mg/kg/day requires a suitable current weight.

Correct criterion for the route

In EMA Annex Revision 5 check the excipient row, route, threshold/unit, specific warning and update date. Labelling declaration and clinical acceptance of exposure are separate decisions. Do not interpret a declaration threshold as a universal safety limit.

Clinical decision and reformulation

Assess allergy, intolerance, age and relevant conditions with the clinical lead. Removing/replacing an excipient requires reassessment of compatibility, dissolution/dispersion, preservation and BUD; reducing one risk cannot justify loss of dose or quality.

Controlled record

F-021 records calculations, sources, individualised decision and review. Do not publish patient data. For feeding tubes add administration site, device, critical osmolality/viscosity considerations and approved SOP-027 instructions.

Sources and references

  1. EMA/European Commission — Excipients in labelling and package leaflet, Annex Revision 5Revision 5, first published 5 December 2025; XLSX annexCurrent version Revision 5; row-specific route, threshold, warning and update dateAuthorised-medicine excipient labelling and safety-information source. Clinical warning review is transferable; declaration thresholds are not universal safety limits and pharmacy national obligations require separate assessment.2026-10-14
  2. EMA — Excipients labellingLive official page checked 14 October 2026EU guideline; excipients with known action or effect; background documentsScope and implementation of excipient warnings; official links to individual excipient assessments.2026-10-14
  3. NHS SPS — Choosing medicines for enteral tube administrationCurrent NHS Specialist Pharmacy Service professional advice, checked 14 October 2026Tube characteristics, licensed options, formulation issues and administration siteClinical/pharmaceutical assessment for actual tube and formulation; general advice cannot establish the suitability of an untested compounded preparation.2026-10-14
  4. NAPRA — Guidance Document for Pharmacy Compounding of Non-sterile PreparationsMarch 2018, clarification January 2022Sections 5, 6 and 7; master/batch records, delivery, qualityQuality-system implementation; historical BUD table not substituted for 2022 USP revision2026-10-14